Among 659 infants of 30 weeks' gestation or less born in a regional perinatal centre between 1983 and 1989, 195 were ventilated for four days or more and survived to 28 days, and 87 of these developed chronic lung disease. There was a sevenfold increase in the annual incidence of chronic lung disease over time. During the same period there were significant increases in the number of infants who survived, the incidence of septicaemia, and the use of parenteral lipid emulsions. Chronic lung disease was significantly associated with low birth weight, shorter gestation, duration of ventilation, vaginal delivery, sepsis, and the use of lipid. Respiratory and physiological, measurements at 96 hours were significantly worse in infants who subsequently developed chronic lung disease. Initial logistic regression showed that gestation, arterial carbon dioxide tension (Paco2), and ventilation rate at 96 hours; and birth in 1988 or 1989, were independently associated with chronic lung disease, but when septicaemia and use of lipid during the first 21 days were included, only gestational age (odds ratio 0.64, 95% confidence interval (CI), 0-49 to 0-81 for each week) and use of lipid (odds ratio 8-1, 95% CI, 2-32 to 28.0) remained significantly associated with chronic lung disease.
Since the introduction of mechanical ventilation for the treatment of severe respiratory distress syndrome in preterm infants, the main complication limiting successful outcome has been chronic lung disease. This is usually defined as oxygen dependence at 28 days of life in an infant with a history of mechanical ventilation during the first week of life and characteristic radio- x2 for trend=25-5, p<000001.
graphic changes in the lung fields. First described by Northway et al,' it has variously been attributed to oxygen toxicity, barotrauma, infection, and the vulnerability of the lungs in very preterm infants.2 During recent years many centres have reported an increasing incidence of chronic lung disease, and the incidence varies considerably among centres. It has been suggested that the rising incidence is related to the survival of an increasingly vulnerable population of infants of lower gestational age who would previously have died. Differences in respiratory management have been suggested as one explanation for the variation in incidence among similar centres.3 A considerable rise in the numbers of infants with chronic lung disease has recently been observed in the Mersey regional neonatal intensive care unit, and this study was initiated to see if this change could be explained by changes in the population alone, or whether factors such as changes in management or increased survival played a part.
Patients and methods
Infants of 24 to 30 weeks' gestation admitted to the Mersey neonatal intensive care unit between 1 January 1983 and 31 December 1989 were included in the study if they were born in the hospital, were ventilated for at least the first four days of life, and survived to at least 28 days (table 1) . Infants born at other hospitals and admitted later were not included because of incompleteness of early physiological data. Infants were considered to have chronic lung disease if they were oxygen dependent at 28 days, had received mechanical ventilation, and had characteristic radiographic changes.
Descriptive, respiratory, and physiological variables were abstracted from the clinical and intensive care records, which had been stored on microfiche. Descriptive variables included birth weight; gestation; sex; number of days ventilated; whether transferred to the centre in utero; use of pancuronium; use of parenteral lipid emulsions; singleton or multiple delivery; caesarean section; occurrence of pneumothorax, persistent ductus arteriosus, or septicaemia; and the presence of chronic lung disease. Persistent ductus arteriosus was defined as the presence of clinical signs sufficient to lead to a change in management such as fluid restriction, and septicaemia as a positive blood culture. Parenteral lipid emulsions (Intralipid 20%, KabiVitrum) were given through peripheral or central lines at a rate of 5 ml/kg/day, increasing over four days to a maximum of 20 ml/kg/day. These variables were examined initially, together (table 4) . If a particular measurement had not been recorded exactly at one of the required times, the next recording was taken. All blood gas measurements were made in arterial samples and all blood pressure recordings were taken from catheters in the aorta or radial artery. Alveolar:arterial (A:a) ratios were computed from the blood gas measurements and the fractional inspiratory oxygen (FIo2-) (table  1) , this cannot account fully for the observed increase in chronic lung disease. If this were so, the numbers of neonatal deaths together with the number of infants in oxygen at 28 days should form a similar proportion of the total population in each year. As seen in table 1, this proportion increased during the seven year period from 42% to 77%. A number of respiratory and physiological measurements made at 96 hours of age were significantly associated with chronic lung disease. In the logistic regression only Paco2 and respiratory rate at 96 hours remained significantly associated with chronic lung disease before septicaemia and lipid use were taken into account. The improved survival of the very immature that has clearly occurred, especially in the last two years of this study, could have been the result of a more intensive attitude to ventilation of this group of infants. Kraybill et al suggested that the observed variation in the incidence of chronic lung disease among a number of neonatal intensive care units in the United States was attributable to differences in the intensity of mechanical ventilation, as shown by the lower Paco2 at 48 hours of age reported from centres with higher rates of chronic lung disease.4 The differences seen in this study were in the opposite direction, implying that infants who developed chronic lung disease were sicker at 96 hours of age rather than overventilated at 48 hours. The lack of an independent association between respiratory variables and the occurrence of chronic lung disease as previously shown suggests that while methods of ventilation may account for differences in chronic lung disease rates among centres, they do not explain the recent increases in incidence within centres.
The increase in the incidence of septicaemia was almost entirely related to an increase in coagulase negative staphylococcal infection. Septicaemia, though strongly associated with chronic lung disease in the univariate analysis, failed to achieve independent association in the logistic regression model after lipid use had been allowed for. Though septicaemia could be causally associated with chronic lung disease, it is also probable that infants who developed chronic lung disease were more prone to infection. The use of lipid emulsions during the first 21 days of life was strongly associated with chronic lung disease, and when it was entered in the regression model it was the only factor to account for the higher incidence of chronic lung disease in 1988 and 1989.
The association between chronic lung disease and the use of lipid could be explained by lipid being given mainly to sicker infants. Examination of lipid prescription in this group during the study period, however, showed a pronounced change in the age at which it was started. In particular, much earlier use of lipid was made in the last two years (table 6) in the absence of any significant change in the early severity of illness as measured by the respiratory and physiological variables. The use of lipid emulsions in sick preterm infants has been associated with higher rates of coagulase negative staphylococcal sepsis,6 as was the case in this study, when 81% of infants receiving lipid became septicaemic, compared with 40% of those who did not (p<O0OOOl). Giving lipid to preterm infants is associated with an excess generation of free radical induced lipid peroxidation, and thromboxane production,7 and free radical induced lung damage has been proposed as a factor in the genesis of chronic lung disease.8 Recently a small clinical trial of lipid given for five days to preterm infants undergoing intensive care showed a significant excess of chronic lung disease and retinopathy in treated infants compared with controls.9
The earlier use of parenteral lipid solutions on this unit was introduced because of concern over poor growth in these sick, very low birthweight infants when amino acids and dextrose/electrolyte solutions alone were used for nutrition. It is likely that this exposed a large number of infants in the earlier stages of hyaline membrane disease to lipid, when they were most vulnerable to lung injury, and that this change in practice accounted for the increase in chronic lung disease seen in recent years.
Until further evidence is available, the use of parenteral lipid emulsions should be restricted to older preterm infants, or to those without respirator-y symptoms. In sick preterm infants any theoretical gains made from early parenteral lipid infusion are outweighed by an increase in the incidence of chronic lung disease in the following weeks and months.
